Screener
Theravance Biopharma TBPH Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The source filing: Theravance Biopharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:00 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056760
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Operating lease liabilities | (2,199) | (1,664) |
| Unrecognized tax benefits | 1,474 | 1,285 |
| Other long-term liabilities | (69) | 68 |
| Net cash provided by operating activities | 73,279 | 43,039 |
| Investing activities | ||
| Purchases of marketable securities | (43,407) | (1,968) |
| Maturities of marketable securities | 96,000 | 32,600 |
| Net cash provided by investing activities | 52,593 | 30,632 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Theravance Biopharma's operating cash flow?
- Theravance Biopharma (TBPH) reported operating cash flow of $73.28M in Q1 2026.
- How has Theravance Biopharma's operating cash flow changed year-over-year?
- Theravance Biopharma's operating cash flow increased by 70.3% year-over-year, from $43.04M to $73.28M.
- What is the long-term trend for Theravance Biopharma's operating cash flow?
- Over 3 years (2021 to 2024), Theravance Biopharma's operating cash flow has grown at a -61.9% compound annual growth rate (CAGR), from -$207.86M to -$11.54M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.
Ask your AI about Theravance Biopharma's operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude